Dexcom (DXCM) analyst forecast and price target
Analyst forecast
Consensus of 32 analyst ratings
Based on 15 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BTIG | Maintained | Buy | $96.00 from $90.00 | Oct 12, 2026 |
| Barclays | Initiated Coverage | Overweight | $115.00 | Oct 7, 2026 |
| RBC Capital | Maintained | Outperform | $105.00 from $90.00 | Oct 1, 2026 |
| Truist Securities | Maintained | Buy | $102.00 from $93.00 | Sep 18, 2026 |
| TD Cowen | Maintained | Buy | $95.00 | Sep 18, 2026 |
| Argus Research | Maintained | Buy | $96.00 from $86.00 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Buy | $90.00 from $82.00 | Aug 3, 2026 |
| Truist Securities | Maintained | Buy | $93.00 from $87.00 | Jul 31, 2026 |
| Benchmark | Maintained | Buy | $82.00 from $77.00 | Jul 31, 2026 |
| Stifel | Maintained | Buy | $95.00 from $90.00 | Jul 31, 2026 |
| Wells Fargo | Maintained | Overweight | $90.00 from $85.00 | Jul 31, 2026 |
| Piper Sandler | Maintained | Overweight | $95.00 from $88.00 | Jul 31, 2026 |
| BTIG | Maintained | Buy | $90.00 from $80.00 | Jul 31, 2026 |
| JP Morgan | Maintained | Neutral | $82.00 from $65.00 | Jul 31, 2026 |
| Mizuho | Maintained | Outperform | $95.00 from $90.00 | Jul 31, 2026 |
| RBC Capital | Maintained | Outperform | $90.00 from $85.00 | Jul 31, 2026 |
| Citigroup | Maintained | Buy | $88.00 from $84.00 | Jul 31, 2026 |
| UBS | Maintained | Buy | $96.00 | Jul 28, 2026 |
| Truist Securities | Maintained | Buy | $87.00 from $80.00 | Jul 16, 2026 |
| Mizuho | Maintained | Outperform | $90.00 from $85.00 | Jul 15, 2026 |
Frequently asked questions
What is the price target for DXCM stock?
The average 12-month analyst price target for Dexcom (DXCM) is $94.80, with a high estimate of $115.00 and a low of $82.00, across 15 analysts.
Is DXCM a buy, sell, or hold?
Analysts covering Dexcom currently average a Buy rating: 27 buy, 5 hold and 0 sell, from 32 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for DXCM?
The average price target of $94.80 implies 11.45% upside from the last price of $85.06.
What is the latest analyst rating on DXCM?
On Oct 12, 2026, BTIG maintained Dexcom at Buy with a price target of $96.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.